Melissa discusses CRRT use on patient with life-threatening arrythmia
"I just remember he was suffering from a life-threatening arrhythmia, attributed to the potassium levels. And he was too unstable for normal dialysis. Because we had that option (CRRT), we were able to decrease his serum potassium rapidly, without worsening his hypotension, without worsening his other organ failure, and stop the arrhythmogenic situation."
Melissa Bastin-Thompson, PharmD, BCPS
Becca talks about using CRRT on a cardiac-arrest patient
"We had a cardiac arrest patient who was still not talkative after hypothermic protocol. We did CRRT on him just to see if it would help. I came in on Monday and he’s talking and making jokes. And I mean it was just amazing…"
Becca Bauer, RN
Dr. Aycinena discusses his experience with CRRT for patient with mantle cell lymphoma
"The most dramatic cases that I have experienced both had mantle cell lymphoma. I remember one patient came in loaded on pressors…we thought was going to pass away and he did a one-eighty, and within 24 hours was off any pressors. I think the (CRRT) combined with the chemotherapy really made a difference."
Juan Carlos Aycinena, MD
Jillian discusses use of CRRT on patient with HUS
"We had a young girl come in that ended up having HUS. And she was literally on her deathbed. We hooked her up (to CRRT) and three days later she was extubated, a week and a half later she was out of the ICU, and two weeks later back at school."
Jillian Kouns, RN
Indications and Important Risk Information
The PRISMAFLEX and PRISMAX Systems are intended for:
PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances
Important Risk Information
PHOXILLUM and PRISMASOL replacement solutions are contraindicated in patients with known hypersensitivities to these products.
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure.
PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.
PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly.
The following adverse reactions have been identified during post-approval use with these or other similar products and therefore may occur with use of PHOXILLUM or PRISMASOL: Metabolic acidosis, hypotension, acid-based disorders, electrolyte imbalances including calcium ionized increased, hyperphosphatemia, hypophosphatemia, fluid imbalance.
For more information, please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information or visit baxterpi.com.
PRISMASATE Intended Use
PRISMASATE Dialysate Formula is intended for treatment of acute kidney disease (renal failure) using Continuous Renal Replacement Therapies, such as continuous hemodialysis and hemodiafiltration aimed at normalizing the composition of the blood. It may also be used in case of drug poisoning with dialyzable or filterable substances.
MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.